海辰药业(300584) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 was ¥162,203,581.18, a decrease of 2.39% compared to ¥166,174,066.04 in the same period last year[8] - Net profit attributable to shareholders was ¥13,509,866.40, down 21.30% from ¥17,167,277.16 year-on-year[8] - The net profit after deducting non-recurring gains and losses was ¥13,045,757.33, reflecting a decline of 22.11% compared to ¥16,748,136.72 in the previous year[8] - Basic and diluted earnings per share were both ¥0.1126, down 21.31% from ¥0.1431 in the previous year[8] - The company achieved a sales revenue of 158 million, representing a year-on-year increase of 8.23%, and a net profit of 19.96 million, up 17.51% year-on-year[19] - The company reported a decrease in current liabilities to CNY 161,059,571.70 from CNY 169,811,406.27[42] - The total profit for Q1 2021 was CNY 14,632,820.18, down from CNY 19,463,487.32 in the previous year[46] - The total comprehensive income for Q1 2021 was CNY 13,297,482.78, down from CNY 17,036,254.07 in the same period last year[47] Cash Flow - The net cash flow from operating activities was ¥18,153,992.05, a significant improvement from a negative cash flow of ¥9,632,384.35 in the same period last year[8] - The operating cash inflow for the current period is CNY 178,803,026.03, an increase of 13.0% compared to CNY 157,384,675.64 in the previous period[54] - The cash inflow from investment activities is CNY 30,062,166.66, up from CNY 20,067,854.83, marking a 49.9% increase[54] - The net cash flow from investment activities is negative at CNY -7,659,685.62, an improvement from CNY -58,868,747.24 in the previous period[54] - The cash inflow from financing activities decreased to CNY 70,000,000.00 from CNY 80,000,000.00, a decline of 12.5%[55] - The net cash flow from financing activities is negative at CNY -1,725,833.33, compared to a positive CNY 48,394,971.95 in the previous period[55] Assets and Liabilities - Total assets at the end of the reporting period were ¥909,113,506.69, a slight increase of 0.29% from ¥906,518,927.96 at the end of the previous year[8] - Total liabilities decreased to CNY 207,093,835.30 from CNY 216,385,608.40[42] - Owner's equity increased to CNY 706,137,569.27, up from CNY 686,420,006.66[42] - Accounts receivable decreased to ¥82,890,313.90 from ¥86,419,628.88, indicating a decline of about 4.1%[36] - Inventory levels decreased to ¥64,227,828.94 from ¥71,578,195.78, representing a reduction of approximately 10.3%[36] Shareholder Information - The total number of shareholders at the end of the reporting period was 7,479, with the largest shareholder holding 42.08% of the shares[12] - The top five customers contributed 10.96% of total sales, with a sales amount of 17.77 million, down from 15.38% in the previous year[22] - The first customer generated revenue of CNY 5,120,489.50, representing 3.16% of total sales in Q1 2021, down from 7.98% in the previous year[23] Investment and R&D - The company has cumulatively invested CNY 19,667.36 million from the raised funds, with a total raised amount of CNY 19,845.7 million[26] - The new drug research and development project has utilized 93.51% of the adjusted investment amount of CNY 4,345.74 million[26] - The marketing channel network construction project has achieved an investment progress of 102.28% against the committed amount of CNY 1,000 million[26] - The company has made adjustments to its new drug research project, including changes in implementation location and methods, which have been approved by the board of directors[27] Risk Factors and Compliance - The company has not encountered any overdue commitments from actual controllers, shareholders, or related parties during the reporting period[24] - There were no significant adverse risk factors affecting the company's future operations reported in the current period[24] - The company has not encountered any violations regarding external guarantees during the reporting period[29] - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[30] Changes in Financial Reporting - The company has implemented new leasing standards effective January 1, 2021, impacting the financial reporting[66]